News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
https://www.siam.in/ Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
On August 10, ProKidney Corp. (NASDAQ:PROK) reported second-quarter financial results that doubled as a status update on the biggest bet in its history: a cell therapy for chronic kidney disease that is now one step closer to a verdict. The clinical-stage company completed enrollment โฆ
Sharemaestro market context Price below Trend Line 52 weeks -46.1% ยท Next-week setup negative 26.9%ProKidney director Brian Pereira sold 757,164 shares of Class A Common Stock for approximately $1.07 million between August 18 and August 20, 2026. The sales were made at prices ranging from $1.3712 to $1.4407 per share, leaving him with zero beneficial ownership. Meanwhile, ProKidney โฆ
ProKidney Director Brian JG Pereira sold his entire holding of Class A Common Stock over three consecutive trading days, from August 18 to August 20, 2026. These transactions, both direct and indirect through a trust, were open-market sales. Following these sales, Pereira holds no โฆ
ProKidney Corp. (PROK) director Brian J. G. Pereira reported selling a total of 757,164 shares of Class A Common Stock between August 18โ20, 2026. The sales included both direct holdings and shares held indirectly by the Brian J. G. Pereira 2012 Irrevocable Trust, at โฆ
ProKidney Corp. (Nasdaq: PROK) announced its second-quarter 2026 financial results and business highlights, notably completing enrollment for the accelerated approval efficacy analysis of its Phase 3 PROACT 1 study, with topline results expected in Q2 2027. The company is on track for full PROACT โฆ
Sharemaestro market context Price below Trend Line 52 weeks -46.1% ยท Next-week setup negative 26.9%ProKidney Corp. reported increased net losses and higher R&D expenses for Q2 2026, with a net loss of $(28,422) thousand compared to $(16,552) thousand in Q2 2025. Total operating expenses rose to $48,523 thousand, driven by a significant increase in research and development costs. โฆ
Morgan Stanley and its affiliate, Morgan Stanley Investment Management Inc., have reported their current beneficial ownership in ProKidney Corp. Class A common stock through a Schedule 13G/A amendment. Both entities now hold a 4.7% stake, individually owning approximately 9.65 million and 9.64 million shares โฆ
ProKidney Corp. reported a net loss of $89.1 million for the first half of 2026 and flagged substantial doubt about its ability to continue as a going concern, as its current cash and marketable securities of $181.6 million are not expected to fund operations โฆ
ProKidney Corp. (PROK) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.13 per share a year ago. These figures are adjusted for non-recurring items. This quarterly โฆ
Sharemaestro market context Price below Trend Line 52 weeks -46.1% ยท Next-week setup negative 26.9%ProKidney Corp. director Brian J.G. Pereira converted 757,164 paired Class B common stock and ProKidney Holdings, LLC common units into an equal number of Class A common shares on August 4, 2026. These transactions, which included both directly held and trust-held securities, were reported โฆ
Search by ticker symbol or company name and select a result to open its chart.
Start typing to find a stock or ETF.
Choose one or more countries for market search, or include every covered market.
Currently searching United States